Research suggests: Synergistic effects on weight loss exceeding predictions from single or dual receptor activation Complementary regulation of both energy intake (primarily GLP-1 and GIP) and energy expenditure (primarily glucagon) Balanced effects on glucose metabolism through multiple mechanisms Potential cardiovascular benefits through lipid metabolism improvements and blood pressure reduction [CALLOUT BOX Highlighted] Mechanistic Insight: GLP3 s triagonist approach represents an evolution beyond dual GLP-1/GIP agonism, with the addition of glucagon receptor activation appearing to enhance weight loss efficacy and metabolic benefits
Retatrutide is a synthetic triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously
b Hanson et al., c Dooley et al., d Lohman and Remington, e Schwarzlnder et al., f Dihydrolipoic acid (DHLA, reduced form), Lipoic acid (LA, oxidized form)
Oxidation of the Cys residue in the active site of PTPs by ROS abrogates its nucleophilic properties, thereby inhibiting PTP activity (87)
This gradual adjustment minimizes side effects while maximizing therapeutic benefits